Management of Pregnant Patients with Elevated ANA and Anti-dsDNA

Serological Testing

The American College of Rheumatology recommends testing for antiphospholipid antibodies (aPL) to predict thrombotic events (OR 12.1), preeclampsia (OR 2.3), and pregnancy loss, and this testing should be done once as these antibodies remain stable during pregnancy 1, 2, 4
Testing for anti-Ro/SSA and anti-La/SSB antibodies is recommended to assess the risk of neonatal lupus and congenital heart block, with a 0.7-2% risk of congenital heart block, and serial fetal echocardiography should be planned for patients with positive anti-Ro/SSA antibodies 1, 2, 4
The European League Against Rheumatism suggests establishing baseline complement levels (C3 and C4) and monitoring serological activity, as declining complement levels during pregnancy predict disease flares (OR 5.3) and pregnancy loss 5, 6
Quantifying anti-dsDNA antibody titers using Farr assay or CLIFT is recommended for high specificity, and rising titers can differentiate SLE flare from preeclampsia 5, 6, 7

The American College of Rheumatology recommends evaluating for lupus nephritis, which strongly predicts poor maternal (RR 9.0 for renal flare) and fetal outcomes (OR 18.9 for preterm delivery), through urinalysis with microscopy, 24-hour urine protein or spot protein:creatinine ratio, and serum creatinine and calculated GFR 5, 6

The European League Against Rheumatism suggests documenting baseline SLE activity using validated pregnancy-specific indices, and active disease at conception increases the risk of flares during pregnancy (RR 2.1) and adverse outcomes (OR 5.7 for pregnancy loss, 6.5 for preterm delivery) 4, 5, 6

The American College of Rheumatology recommends planning serial fetal echocardiography from weeks 16-26 for patients with anti-Ro/SSA or anti-La/SSB positive antibodies, and weekly fetal echocardiography for patients with a history of neonatal lupus 1, 3

The American College of Rheumatology recommends initiating hydroxychloroquine immediately for patients not already on it, as it reduces flares and improves pregnancy outcomes, and adding low-dose aspirin (81-100 mg daily) ± heparin for patients with aPL positive based on APS classification 1, 2, 3
Establishing a trimester-based monitoring schedule, including repeat complement, anti-dsDNA, CBC, and renal function at least once per trimester, is recommended 1, 3